Xiao-Ling Xu - Search Results

Year	Number of Results
2000	1
2006	3
2007	1
2008	1
2009	3
2010	3
2011	1
2012	3
2013	5
2014	7
2015	15
2016	8
2017	5
2018	7
2019	10
2020	6
2021	9
2022	5
2023	10

1

Endogenous Enzyme-responsive Nanoplatforms for Anti-tumor Therapy.

Lou XF, Du YZ, Xu XL. Lou XF, et al. Among authors: xu xl. Curr Drug Targets. 2021;22(8):845-855. doi: 10.2174/1389450122666210114095614. Curr Drug Targets. 2021. PMID: 33459230 Review.

2

Nanodevices for deep cartilage penetration.

Xu XL, Xue Y, Ding JY, Zhu ZH, Wu XC, Song YJ, Cao YL, Tang LG, Ding DF, Xu JG. Xu XL, et al. Acta Biomater. 2022 Dec;154:23-48. doi: 10.1016/j.actbio.2022.10.007. Epub 2022 Oct 12. Acta Biomater. 2022. PMID: 36243371 Review.

3

Current Drug Targets for Thymic Neoplasms.

Xu XL, Mao WM. Xu XL, et al. Curr Cancer Drug Targets. 2015;15(7):593-603. doi: 10.2174/1568009615666150616124155. Curr Cancer Drug Targets. 2015. PMID: 26077729 Review.

4

Novel Antibacterial Strategies for Combating Bacterial Multidrug Resistance.

Xu XL, Kang XQ, Qi J, Jin FY, Liu D, Du YZ. Xu XL, et al. Curr Pharm Des. 2019;25(44):4717-4724. doi: 10.2174/1381612825666191022163237. Curr Pharm Des. 2019. PMID: 31642769 Review.

5

Recent advances in enzyme-related biomaterials for arthritis treatment.

Liu XH, Ding JY, Zhu ZH, Wu XC, Song YJ, Xu XL, Ding DF. Liu XH, et al. Among authors: xu xl. Front Chem. 2022 Aug 16;10:988051. doi: 10.3389/fchem.2022.988051. eCollection 2022. Front Chem. 2022. PMID: 36051622 Free PMC article. Review.

6

The Potential of Drug Delivery Nanosystems for Sepsis Treatment.

Shi Y, Zhu ML, Wu Q, Huang Y, Xu XL, Chen W. Shi Y, et al. Among authors: xu xl. J Inflamm Res. 2021 Dec 19;14:7065-7077. doi: 10.2147/JIR.S339113. eCollection 2021. J Inflamm Res. 2021. PMID: 34984019 Free PMC article. Review.

7

UFMylation of HRD1 regulates endoplasmic reticulum homeostasis.

Luo H, Jiao QB, Shen CB, Gong WY, Yuan JH, Liu YY, Chen Z, Liu J, Xu XL, Cong YS, Zhang XW. Luo H, et al. Among authors: xu xl. FASEB J. 2023 Nov;37(11):e23221. doi: 10.1096/fj.202300004RRRR. FASEB J. 2023. PMID: 37795761

8

Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma.

Cheng L, Li N, Xu XL, Mao WM. Cheng L, et al. Among authors: xu xl. Curr Drug Targets. 2020;21(15):1606-1612. doi: 10.2174/1389450121666200719011234. Curr Drug Targets. 2020. PMID: 32682370 Review.

9

Recent advances in near-infrared II imaging technology for biological detection.

Zhang NN, Lu CY, Chen MJ, Xu XL, Shu GF, Du YZ, Ji JS. Zhang NN, et al. Among authors: xu xl. J Nanobiotechnology. 2021 May 10;19(1):132. doi: 10.1186/s12951-021-00870-z. J Nanobiotechnology. 2021. PMID: 33971910 Free PMC article. Review.

10

Stimuli-responsive Drug Delivery Systems as an Emerging Platform for Treatment of Rheumatoid Arthritis.

Xu XL, Lu KJ, Yao XQ, Ying XY, Du YZ. Xu XL, et al. Curr Pharm Des. 2019;25(2):155-165. doi: 10.2174/1381612825666190321104424. Curr Pharm Des. 2019. PMID: 30907308 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

94 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year